Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05719714 · ClinicalTrials.gov registry record · Phase 1
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
A Phase 1 study of Heart Failure and Chronic Kidney Diseases, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05719714: Recruiting Phase 1 study of Heart Failure and Chronic Kidney Diseases, sponsored by Northwestern University.
NCT05719714 is a Phase 1 study of Heart Failure and Chronic Kidney Diseases that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 60 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05719714, a Phase 1 study of Heart Failure and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Primary Outcome
2D-speckle tracking echocardiography
Conditions Studied
Interventions
- DRUG Dapagliflozin 10 MG [Farxiga]
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT05719714 shows while recruiting
NCT05719714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Dapagliflozin 10 MG [Farxiga] is the first listed.
NCT05719714 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05719714 about?
NCT05719714 is a clinical study titled "Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease". The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients...
What is the current status of trial NCT05719714?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-01-16. Estimated completion is 2026-09-30.
What conditions does trial NCT05719714 study?
This clinical trial studies the following conditions: Heart Failure, Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases.
What interventions are being tested in trial NCT05719714?
The interventions under investigation include: Dapagliflozin 10 MG [Farxiga] (DRUG).
Who is sponsoring clinical trial NCT05719714?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05719714 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05719714's enrollment target sits among peer trials
60 254th of 397 higher than 131 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI